|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...142143144145146147148149150151152...156157» |
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Enrollment open: Canadian Avonex PEN Productivity Study (clinicaltrials.gov) - Mar 28, 2012
P=N/A, N=500, Recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting
- | NI-071 (infliximab biosimilar) - Sanofi, Nichi / Iko, Binex, Aprogen, Elea Labs
New P1 trial: Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 28, 2012
P1, N=14, Completed, Sponsor: Nichi-Iko Pharmaceutical Co.,Ltd.
- || Xeljanz (tofacitinib) / Pfizer
Clinical: Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550 (clinicaltrials.gov) - Mar 27, 2012
P=N/A, N=162, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=300 --> 162
- Clinical: Web-based Support During Pregnancy and Early Motherhood in Women With Type 1 Diabetes (MODIAB-web) (clinicaltrials.gov) - Mar 27, 2012
P=N/A, N=160, Recruiting, Sponsor: Göteborg University
- | TOUR006 / Tourmaline Bio
Trial completion: Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 27, 2012
P1, N=41, Completed, Sponsor: Pfizer
N=300 --> 162 Active, not recruiting --> Completed
- ||| Xeljanz (tofacitinib) / Pfizer
Clinical: Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550 (clinicaltrials.gov) - Mar 27, 2012
P=N/A, N=162, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Kineret (anakinra) / SOBI
Clinical: Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=80, Active, not recruiting, Sponsor: University of Athens
- Enrollment open: Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=1920, Recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | NN9828 / Novo Nordisk
New P1 trial: Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 26, 2012
P1, N=32, Completed, Sponsor: Novo Nordisk
- Enrollment change: Association of Thyroid Autoimmunity and Chronic Urticaria (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=155, Completed, Sponsor: Far Eastern Memorial Hospital
Not yet recruiting --> Recruiting N=100 --> 155
- |||| Nanozora (ozoralizumab) / Sanofi, Taisho
Trial completion: Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 25, 2012
P2, N=266, Completed, Sponsor: Ablynx
N=100 --> 155 Recruiting --> Completed
- Trial completion: Association of Thyroid Autoimmunity and Chronic Urticaria (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=155, Completed, Sponsor: Far Eastern Memorial Hospital
Recruiting --> Completed Recruiting --> Completed
- ||||| Tavalisse (fostamatinib) / Rigel
New P2 trial: Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 25, 2012
P2, N=135, Completed, Sponsor: AstraZeneca
- Trial completion: Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=84, Completed, Sponsor: Örebro County Council
Recruiting --> Completed Recruiting --> Completed
- relamorelin (RM-131) / AbbVie
Enrollment change: Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis (clinicaltrials.gov) - Mar 22, 2012
P1, N=20, Completed, Sponsor: Rhythm Pharmaceuticals, Inc.
Recruiting --> Completed N=10 --> 20
- | famotidine/ibuprofen / Generic mfg.
New P4 trial: Open-label Safety and Pharmacokinetic Study of DUEXIS (clinicaltrials.gov) - Mar 22, 2012
P4, N=30, Recruiting, Sponsor: Horizon Pharma, Inc.
- |||| tofacitinib / Generic mfg.
Pneumococcal vaccines: A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo (clinicaltrials.gov) - Mar 22, 2012
P2, N=223, Completed, Sponsor: Pfizer
N=10 --> 20 Recruiting --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. (clinicaltrials.gov) - Mar 21, 2012
P2, N=64, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- | Trial suspension: Gender Solutions Natural Knee Post-Market Study (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=300, Suspended, Sponsor: Zimmer, Inc.
Recruiting --> Completed Not yet recruiting --> Suspended
- Enrollment change: IMMUTRI: Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=72, Completed, Sponsor: Institut Jerome Lejeune
Not yet recruiting --> Suspended N=60 --> 72
- Biomarker, Trial completion: Ultrasonography in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Mar 20, 2012
P0, N=95, Completed, Sponsor: University of Aarhus
N=60 --> 72 Recruiting --> Completed
- Trial completion: IMMUTRI: Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=72, Completed, Sponsor: Institut Jerome Lejeune
Recruiting --> Completed Recruiting --> Completed
- || Enrollment change, Immunomodulating: Cognitive Effects of Immunomodulatory Drugs in MS (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=96, Completed, Sponsor: Sharon Lynch, MD
Recruiting --> Completed N=145 --> 96
- ||| Trial completion, Immunomodulating: Cognitive Effects of Immunomodulatory Drugs in MS (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=96, Completed, Sponsor: Sharon Lynch, MD
N=145 --> 96 Active, not recruiting --> Completed
- ||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment change, Monotherapy: A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 19, 2012
P3, N=311, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed N=232 --> 311
- | Saphnelo (anifrolumab) / AstraZeneca
New P2 trial: Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus. (clinicaltrials.gov) - Mar 19, 2012
P2, N=19, Active, not recruiting, Sponsor: AstraZeneca
- |||| MP-435 / J&J
Trial completion, Combination therapy: Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 19, 2012
P2, N=112, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
N=232 --> 311 Active, not recruiting --> Completed
- ||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Monotherapy: A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 19, 2012
P3, N=311, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Combination therapy: A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Mar 19, 2012
P3, N=269, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Diamyd (recombinant 65 kDa isoform of human glutamic acid decarboxylase) / Diamyd Medical, Januvia (sitagliptin) / Merck (MSD)
Trial termination, Immunomodulating: Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes (clinicaltrials.gov) - Mar 19, 2012
P2, N=7, Terminated, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed Completed --> Terminated; Changes to study personnel.
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial, Real-world evidence, Real-world: Good EULAR Response In Patients With Early Rheumatoid Arthritis (clinicaltrials.gov) - Mar 18, 2012
P4, N=150, Recruiting, Sponsor: Pfizer
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis (clinicaltrials.gov) - Mar 18, 2012
P=N/A, N=15, Completed, Sponsor: University of Manitoba
Completed --> Terminated; Changes to study personnel. Recruiting --> Completed
- Enrollment change: Bone Marrow Autotransplantation in Type 1 Diabetes (clinicaltrials.gov) - Mar 18, 2012
P=N/A, N=3, Completed, Sponsor: Hospital Clinic of Barcelona
Recruiting --> Completed N=10 --> 3
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: DoseFlex: Dosing Flexibility Study in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 15, 2012
P4, N=333, Completed, Sponsor: UCB, Inc.
N=10 --> 3 N=617 --> 333
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS) (clinicaltrials.gov) - Mar 15, 2012
P=N/A, N=719, Completed, Sponsor: Hoffmann-La Roche
N=617 --> 333 N=387 --> 719
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs. (clinicaltrials.gov) - Mar 15, 2012
P4, N=21, Completed, Sponsor: Hoffmann-La Roche
N=387 --> 719 Active, not recruiting --> Completed
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy: A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 15, 2012
P3, N=46, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, HEOR: A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs. (clinicaltrials.gov) - Mar 15, 2012
P4, N=201, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial initiation date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Mar 14, 2012
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Mar 2012
- || Avonex (recombinant IFN-β-1a) / Biogen
Enrollment change: ASPECT: Avonex PEN Satisfaction and Patients Experience Clinical Trial (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=89, Completed, Sponsor: Biogen Idec
Initiation date: Oct 2011 --> Mar 2012 N=200 --> 89
- | Enrollment open: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Mar 14, 2012
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
N=200 --> 89 Not yet recruiting --> Recruiting
- ||| Nerventra (laquinimod) / Active Biotech
Trial initiation date: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease (clinicaltrials.gov) - Mar 13, 2012
P2, N=211, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
Not yet recruiting --> Recruiting Initiation date: Jan 2006 --> Dec 2006
- | cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: PROMESS: Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 13, 2012
P3, N=138, Completed, Sponsor: University Hospital, Bordeaux
Initiation date: Jan 2006 --> Dec 2006 N=360 --> 138
- | cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: PROMESS: Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 13, 2012
P3, N=138, Completed, Sponsor: University Hospital, Bordeaux
N=360 --> 138 Active, not recruiting --> Completed
- Trial completion: Sensori-motor Integration Training in Multiple Sclerosis (clinicaltrials.gov) - Mar 13, 2012
P0, N=80, Completed, Sponsor: Universita di Verona
Active, not recruiting --> Completed Recruiting --> Completed
- | Ilaris (canakinumab) / Novartis
Trial termination: β-SPECIFIC 1: Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) (clinicaltrials.gov) - Mar 12, 2012
P3, N=84, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Completed --> Terminated; recommendation by Data Monitoring Committee
- ||| PF-5230895 / Emergent Biosolutions, Pfizer
Trial completion: Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 12, 2012
P1, N=62, Completed, Sponsor: Pfizer
Completed --> Terminated; recommendation by Data Monitoring Committee Recruiting --> Completed
- |||||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Enrollment open: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (clinicaltrials.gov) - Mar 11, 2012
P3, N=350, Recruiting, Sponsor: CSL Behring
Recruiting --> Completed Not yet recruiting --> Recruiting
- | tregalizumab (BT-061) - ADMA Biologics, T / Balance Therapeutics
Trial completion: Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Mar 11, 2012
P2, N=49, Completed, Sponsor: Biotest
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | baminercept (BG 9924) / Biogen
New P2 trial: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sj (clinicaltrials.gov) - Mar 11, 2012
P2, N=72, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)